Analytical Methods and Stability Testing of Biopharmaceuticals

Protein Formulation and Delivery, Second Edition

Volumn , Issue , 2007, Pages 73-108

  Hoffmann, Helmut ^a   Heberle, Sandra Pisch ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85144149840     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849379529-7     Document Type: Chapter

References (154)

1. Lawrence S. Nat Biotechnol 2005; 23:1466.
2. Pavlou A, Reichert J. Nat Biotechnol 2004; 22:1513-1519.
3. Werner RG. Clinical Pharmacology of Biotechnology Products. Amsterdam: Elsevier Science Publishers, 1991:3-22.
4. Butler M. Appl Microbiol Biotechnol 2005; 68:283-291.
5. Chen M et al. Med Res Rev 2005; 25:343-369.
6. Jarvis D. Virology 2003; 310:1-7.
7. Gerngross TU. Nat Biotechnol 2004; 22:1409-1414.
8. Li H. Nat Biotechnol 2006; 24:210-215.
9. Kopp K, Schlüter M, Werner RG. In: Townsend RR, Hotch-kiss AT Jr, eds. Techniques in Glycobiology. New York: Marcel Dekker, 1997:475-489.
10. Note for Guidance on Biotechnological/Biological Products Subject to changes in their Manufacturing Process. CPMP/ICH/5721/03, CHMP, December 2004.
11. Guideline on Comparability of Medicinal Products containing Biotechnology-derived Proteins as Active Substance—Quality Issues CPMP/BWP/3207/00 Rev.1, CPMP, December 2003.
12. Allgaier H. Chimia 1994; 48:464-466.
13. Werner RG, Noe W. Arzneim-Forsch/Drug Res 1993; 43(11):1134-1139.
14. Werner RG, Noe W. Arzneim-Forsch/Drug Res 1993; 43(11):1242-1249.
15. Berthold W, Walter J. Biologicals 1994; 22:135-150.
16. The United States Pharmacopeia. Biotechnology-derived articles. Rockville, MD: U.S. Pharmacopeial Convention, Inc., 1994:1849-1859.
17. Chirino AJ, Mire-Sluis A. Nature Biotechnol 2004; 22:1383-1391.
18. Harris RJ et al. J Chrom B 2001; 752:233-245.
19. Jones AJS. Adv Drug Delivery Rev 1993; 10:29-90.
20. Kopp K, Schlüter M, Werner RG. In: Techniques in Glycobiology. Townsend RR, Hotchkiss AT Jr, eds. New York: Marcel Dekker, 1997:475-489.
21. Hancock WS, Bishop CA, Hearn MTW. Anal Biochem 1979; 92:170-173.
22. Nguyen DN et al. Protein mass spectrometry: applications to analytical biotechnology. J Chromatogr 1995; A705:21-45.
23. Perkins M et al. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm Res 2000; 17:1110-1117.
24. Wang L et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005; 14:2436-2446.
25. Chloupek RC, Harris RJ, Leonard CK, et al. J Chromatogr 1989; 463:375-396.
26. Dougherty JJ, Snyder LM, Sinclair RL, Robbins RH. Anal Biochem 1990; 190:7-20.
27. Edman P, Begg C. Eur J Biochem 1967; 1:80-91.
28. Jones AJS, Garnick RL. In: Lubniecki AS, ed. Large-Scale Mammalian Cell Culture Technology. New York: Marcel Dekker, 1990:543-566.
29. Gibson BW, Yu Z, Gillece-Castro B, Aberth W, Walls FC, Burlingame AL. In: Hugli TE, ed. Techniques in Protein Chemistry. Vol. 3. San Diego: Academic Press, 1989:135-151.
30. Hernandez P, Müller M, Appel RD. Mass Spectrometry Rev 2006; 25:235-254.
31. Havel HA, Chao RS, Haskel RJ, Thamann TJ. Anal Chem 1989; 61:642-650.
32. Strickland EH. CRC Crit Rev Biochem 1974; 2:113-175.
33. Chen YH, Yang JT, Chau KH. Biochemistry 1974; 13:3350-3359.
34. Johnson WC. Annu Rev Biophys Chem 1988; 17:145-166.
35. Pearlman R, Nguyen TH. Biochemistry 1991; 10:824-830.
36. Bewley TA. Recent Prog Hormone Res 1979; 35:155-213.
37. Jones AJS, O’Connor JV. In: Gueriguian JL, Bransome ED Jr, Outschoorn AS, eds. Hormone Drugs. Rockville, MD: U.S. Pharmacopeia, 1982:335-351.
38. Davio SR, Hageman MJ. In: Wang JY, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs: Case Histories. New York: Plenum Press, 1993:59-90.
39. Susi H, Byler DM. Methods Enzymol 1986; 130:290-311.
40. Surewicz WK, Mantsch HH, Chapman D. Biochemistry 1993; 32:389-394.
41. Arrondo JL, Muga A, Castresana J, Goni FM. Prog Biophys Mol Biol 1993; 59:23-56.
42. Prestrelski SJ, Arakawa T, Carpenter JF. Arch Biochem Biophys 1993; 303:465-473.
43. Van der Weert M et al. Fourier transform infrared spectrometric analysis of protein conformation: effect of sampling method and stress factors. Anal Biochem 2001; 297:160-169.
44. Remmele RL Jr et al. Differential scanning calorimetry: a practical tool for elucidating stability in liquid pharmaceuticals. Biopharm Eur 2000; 56:58-60.
45. Kronman MJ, Holmes L.G. The fluorescence of native, denatured, and reduced-denatured proteins. Photocem. Photobiol 1971; 14:113-134.
46. Burstein EA, Vedenkina NS, Ivkova MN. Photchem Photobiol 1973; 18:263-279.
47. Montreuil J. Pure Appl Chem 1975; 42:431-477.
48. Montreuil J. Adv Carbohydr Chem Biochem 1980; 37:157-223.
49. Tsuda E, Kawanishi G, Ueda M, Masuda S, Sasaki R. Eur J Biochem 1990; 188:405-411.
50. Wolle J, Jansen H, Smith LC, Chan L. J Lipid Res 1993; 34:2169-2176.
51. Parekh RB, Dwek RA, Rudd PM, et al. Biochemistry 1989; 28:7670-7679.
52. Elbein AD. Trends Biotechnol 1991; 9:346-352.
53. Berman PW, Lasky LA. Trends Biotechnol 1985; 3:51-53.
54. Steer CF, Ashwell G. Prog Liver Dis 1986; 8:99-123.
55. Takeuchi M, Inoue N, Strickland TW, et al. Proc Natl Acad Sci USA 1989; 86:7819-7822.
56. Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on IgG effector function: studies with chimeric mouse-human iGG1 antibodies in glycosyl-ation mutants of Chinese hamster ovary cells. J Immunol 1998; 160:3393-3402.
57. Shields RL et al. Lack of fucose on human IgG1 N-Linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-26740.
58. Jefferis R. Glycosylation of human IgG antibodies: relevance to therapeutic applications. Biopharm 2001; 14:19-26.
59. Goochee CF, Monica T. Biotechnology 1990; 8:421-427.
60. Goochee CF, Gramer MJ, Anderson DC, Bahr JB, Rasmussen JR. Biotechnology 1991; 9:1347-1355.
61. Gawlitzek M, Conradt HS, Wagner R. Biotechnol Bioeng 1995; 467:536-544.
62. Borys MC, Linzer DIH, Papoutsakis ET. Biotechnol Bioeng 1994; 43:505-514.
63. Borys MC, Linzer DIH, Papoutsakis ET. Biotechnol 1993; 11:720-724.
64. Gramer MJ, Goochee CF. Biotechnol Prog 1993; 9:366-377.
65. Gramer MJ, Schaffer DV, Sliwkowski MB, Goochee C. Glycobiol 1994; 4:611-616.
66. Hardy MR, Townsend RR. Proc Natl Acad Sci USA 1988; 85:3289-3293.
67. Townsend RR, Hardy MR. Glycobiol 1991; 1:139-147.
68. Mechref Y, Novotny MV. Structural investigations of glycoconjugates at high sensitivity. Chem Rev 2002; 102:321-369.
69. Sheeley DM et al. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal a-linked galactose. Anal Biochem 1997; 247:102-110.
70. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. J Biol Chem 1951; 193:265-275.
71. Bradford MM. Anal Biochem 1976; 72:248-254.
72. Wetlaufer DB. Adv Protein Chem 1962; 17:303-390.
73. Wang YJ. In: Avis KE, Lieberman HA, Lachman L, eds. Pharmaceutical Dosage Forms: Parenteral Medications. New York: Marcel Dekker, 1992:283-319.
74. Winder AF, Gent WLG. Biopolymers 1971; 10:1243-1252.
75. Gill SC, Hippel PH. Anal Biochem 1989; 182:319-326.
76. Bewly TA. Anal Biochem 1982; 123:55-65.
77. Harnes BD, Rickwood D, eds. Gel Electrophoresis of Proteins: A Practical Approach. Oxford: IRL Press, 1981.
78. Kleparnik K, Boocek P. J Chromatogr 1991; 569:3-42.
79. Righetti PB. Isoelectric Focusing: Theory, Methodology, and Applications. Amsterdam: Elsevier, 1983.
80. Righetti PG. In: Creighton TE, ed. Protein Structure: A Practical Approach. Oxford: IRL Press, 1989:23-63.
81. Righetti PG. Immobilized pH Gradients: Theory and Methodology. Amsterdam: Elsevier, 1990.
82. Vesterberg O, Svensson H. Acta Chem Scand 1966; 20:820-834.
83. Nguyen TH, Ward C. In: Wang JY, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs: Case Histories. New York: Plenum Press, 1993:91-134.
84. Canova-Davis E, Teshima GM, Kessler TJ, Lee PJ, Guzzetta AW, Hancock WS. Am Chem Soc Symp 1990; 434:90-112.
85. Pearlman R, Nguyen TH. In: Marshak D, Liu D, eds. Therapeutic Peptides and Proteins: Formulation, Delivery, and Targeting. Plainview, NY: Cold Spring Harbor Laboratory, 1989:23-30.
86. Good DL. Capillary electrophoresis of proteins in a quality control environment. Capillary Electrophoresis of Proteins and Peptides, Methods in Molecular Biology. New Jersey: Human Press Inc, 2004:276.
87. Wehr T, Rodriguez-Diaz R, Zhu M. Capillary Electrophoresis of Proteins, Chroatography Science Series. New York: Marcel Dekker, Inc., 1999:80.
88. Henry MP. In: Oliver RWA, ed. HPLC of Macromolecules: A Practical Approach. Oxford: IRL Press, 1989:9-125.
89. Sluyterman LA Ae, Elgersma O. J Chromatogr 1978; 150:17-30.
90. Sluyterman LA Ae. Trends Biochem Sci 1982; 7:168-170.
91. Reynolds JA, Tanford C. J Biol Chem 1970; 245:5161-5165.
92. See YP, Jackowski G. In: Creighton TE, ed. Protein Structure: A Practical Approach, Oxford: IRL Press, 1989:1-21.
93. Shapiro AL, Vinuela E, Maizel JV. Biochem Biophys Res Commun 1967; 28:815-820.
94. Weber K, Osborne M. J Biol Chem 1969; 244:4406-4412.
95. Laemmli UK. Nature 1970; 27:680-685.
96. Neville DM Jr. J Biol Chem 1971; 246:6328-6334.
97. Harnes BD. In: Harnes BD, Rickwood D, eds. Gel Electrophoresis of Proteins: A Practical Approach. Oxford: IRL Press, 1981:1-91.
98. Gooding KM, Regnier FE. In: Gooding KM, Regnier FE, eds. HPLC of Biological Macromolecules. New York: Marcel Dekker, 1990:47-75.
99. Andrews P. Methods Biochem. Anal 1970; 18:1-53.
100. Whitaker R, Determination of molecular weights of proteins bygel. Anal Chera, 1963 35:1950-53.
101. Van Liedekerke BM, Nelis HJ, Kint JA, Vanneste FW, De Leenheer AP. J Pharm Sci 1991; 80:11-16.
102. Townsend MW, DeLuca PP. J Pharm Sci 1991; 80:63-66.
103. Smith RD, Loo JA, Loo RRO, Busman M, Udseth HR. Mass Spectrom Rev 1991; 10:359-451.
104. Bristow AWT. Mass Spectrometry Rev 2006; 25:99-111.
105. Maquin F, Schoot BM, Devaux PG, Green BN. Rapid Commun Mass Spectrom 1991; 5:299-302.
106. Hillenkamp F, Karas M. Methods Enzymol 1990; 193:280-294.
107. Karas M, Bahr U, Giessmann U. Mass Spectrom Rev 1991; 10:335-357.
108. Beavis RC, Chait BT. Proc Natl Acad Sci USA 1990; 87:6873-6877.
109. Groesbeck MD, Parlow AF. Endocrinology 1987; 120:2582.
110. Gery I, Gershon RK, Waksman BH. J Exp Med 1972; 136:128-142.
111. Gery I, Davies P, Derr J, Krett N, Barranger JA. Cell Immunol 1981; 64:293-303.
112. Gu L, Fausnaugh J. Pharmaceutical biotechnology. In: Wang YJ, Pearlman R, eds. Stability and Characterization of Proteins and Peptid Drugs: Case Histories. Vol. 5. New York: Plenum Press, 1993:221-248.
113. Stewart WE II. The Interferon System. Vienna: Springer Verlag, 1981:13-25.
114. Finter NB. Interferon assays and standards. In: Finger NB, ed. Interferons. Amsterdam: North Holland, 1966:87.
115. Ranby M. Biochim Biophys Acta 1982; 704:461-469.
116. Collen D, Tytgat G, Verstaete M. J Clin Pathol 1968; 21:705-707.
117. Gaffney PJ, Curtis AD. Thromb Haemostasis 1985; 53:134-136.
118. Carlson RH, Garnick RL, Jones AJS, Meunier AN. Anal Biochem 1988; 168:28-435.
119. Jones AJ, Meunier AM. Thromb Haemostasis 1990; 64:455-463.
120. Werner RG, Bassarab S, Hoffman H, Schlüter M. Arzneim Forsch/Drug Res 1991; 41(11):1196-1200.
121. Kung VT, Panfili PR, Sheldon FL, et al. Anal Biochem 1990; 187:220.
122. WHO Epidemiological Records. 1997; 72(20):143-145.
123. Schiff LJ, Moore WA, Brown J, Wisher H. BioPharm 1992; 5(5):36-39.
124. Hill D, Beatrice M. BioPharm 1989; 2(10):28-32.
125. Werner RG, Walter J. BioEngineering 1990; 5(90):14-19.
126. Walter J, Allgaier H. In: Hauser H, Wagner R, eds. Mammalian Cell Biotechnology in Protein Production. Berlin, New York: Walter de Gruyter, 1997; 451(1)-483.
127. CPMP/ICH/295/95. Q5A Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, 1997.
128. CPMP/ICH/294/95. Q5D Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products, 1998.
129. Jones AJS. In: Cleland JL, Langer R, eds. Formulation and Delivery of Proteins and Peptides. Washington, DC: American Chemical Society, 1994:22-45.
130. Banga AK. Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems. Lancaster, PA: Technomic Pub, 1995:61-80.
131. Manning MC, Patel K, Borchardt RT. Pharm Res 1989; 6:903-918.
132. Chang BS, Randall CS, Lee YS. Pharm Res 1993; 10:1478-1483.
133. Back JF, Oakenfull D, Smith MB. Biochemistry 1979; 18:5191-5196.
134. Vermuri S, Beylin I, Sluzky V, Stratton P, Eberlein G, Wang YJ. J Pharm Pharmacol 1994; 46:481-486.
135. Pearlman R, Nguyen T. J Pharm Pharmacol 1992; 44:178-185.
136. Cleland JL, Powell MF, Shire SJ. Crit Rev Thera Drug Carrier Syst 1993; 10:307-377.
137. Winder AF, Gent WLG. Correction of light-scattering errors in spectro-photometric protein determinations. Biopoly 1971; 10:1243-51.
138. Washington C. Particle Size Analysis in Pharmaceutics and Other Industries: Theory and Practice. New York: Ellis Horwood 1992:Chap. 7.
139. Nicoli DF, Benedek GB. Biopolymers 1976; 15:2421-2437.
140. Cleland JL, Wang DIC. Biochemistry 1990; 29:11072-11078.
141. Geigert J. J Parenter Sci Technol 1989; 43(5):220-224.
142. Wallach J, Schlüter M, Werner RG. Stable formulations for biopharmaceuticals. In: Duchene D, ed. Recent Advances in Peptide and Protein Delivery. Minutes of the 8th International Pharmaceutical Technology Symposium, 1997.
143. Oakley BR, Kirsch DR, Morris NR. Anal Biochem 1980; 105:361-363.
144. Merril CR, Goldman D, Sedman SA, Ebert MH. Science 1981; 211:1437-1438.
145. Morrissey JH. Anal Biochem 1981; 117:307-310.
146. Poehling HM, Neuhoff V. Electrophoresis 1981; 2:141-147.
147. Schrier JA, Kenley RA, Williams R, et al. Pharm Res 1993; 10:933-944.
148. Kenley RA, Warne NW. Pharm Res 1994; ll(l):72-76.
149. Powell MF. In: Cleland JL, Langer R, eds. Formulation and Delivery of Proteins and Peptides. Washington, DC: American Chemical Society, 1994:100-117.
150. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Adv Drug Delivery Rev 1993; 10:1-28.
151. ICH Guidance Validation of Analytical Procedures. Target and Methodology, CPMP/ICH/381/95-1CHQ2 (Res).
152. Hoffmann H, Bassarab S, Schlüter M, Werz W, Werner RG. Stability testing of biopharmaceuticals. Paperback APV, Band 32, Stability Testing in the EC, Japan and the USA. Stuttgart: Wissenschaftliche Verlag, 1993:245-272.
153. International Conference on Harmonization. www.emea.europa.eu/htms/human/ich/ichquality.htm. CPMP/ICH/2736/99. Aug. 2003.
154. International Conference on Harmonization. Quality of biotechnological products: stability testing of biotechnological/biological products (Topic Q5C). CPMP/ ICH/138/95. July 1996.